Dr. rer. biol. hum. Sandra Rutzner

Lehrstuhl für Strahlentherapie Department of Radiation Oncology

Development of an immunological prognostic Signature in metastatic Patients who were treated with Immune Checkpoint Inhibitors as part of the ST-ICI Study (2020) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Sun R, Ma H, et al. Conference contribution Effectiveness of ablative Irradiation of all Metastases versus Irradiation of a singular Metastasis in Combination with Immunocheckpoint Inhibitors - clinical Evaluation of prospective STICI Study (2020) Schubert P, Schweizer C, Roesch J, Haderlein M, Rutzner S, Semrau S, Donaubauer AJ, et al. Conference contribution Prognostic Significance of immune-associated Side Effects under Radioimmunotherapy and Immunotherapy alone in Patients of the prospective ST-ICI Study (2020) Schweizer C, Schubert P, Haderlein M, Rutzner S, Semrau S, Donaubauer AJ, Becker I, et al. Conference contribution R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial (2020) Fietkau R, Grützmann R, Wittel UA, Croner RS, Jacobasch L, Neumann UP, Reinacher-Schick A, et al. Journal article Deterioration of Health-Related Quality of Life Scores under Treatment Predicts Longer Survival (2020) Jörling M, Rutzner S, Hecht M, Fietkau R, Distel L Journal article Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial) (2019) Hecht M, Gostian AO, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Hautmann MG, et al. Conference contribution Complete Remission with consecutive Pneumonitis in metastatic Bronchogenic Carcinoma after combination of Radiotherapy and Nivolumab - Immunological Correlate in peripheral Blood (2019) Hecht M, Donaubauer AJ, Becker I, Rutzner S, Lubgan D, Lettmaier S, Haderlein M, et al. Conference contribution Noncurated Data Lead to Misinterpretation of Treatment Outcomes in Patients With Prostate Cancer After Salvage or Palliative Radiotherapy (2019) Rutzner S, Ganslandt OT, Fietkau R, Prokosch HU, Lubgan D Journal article Pradictive Character of Immunophenotyping in peripheral Blood in Patients treated with PD-1 Immunocheckpoint Inhibitors with and without Radiotherapy (Prospective Phase IV Study ST-ICI) (2018) Hecht M, Donaubauer AJ, Harrer A, Rutzner S, Becker I, Lettmaier S, Haderlein M, et al. Conference contribution 12x6Gy-the Erlangen stereotactic radiotherapy treatment concept result in 95% local progression-free survival for bronchial carcinoma and 83% for pulmonary metastases after 3 years (2018) Lubgan D, Rutzner S, Lambrecht U, Fietkau R Conference contribution